Patents by Inventor Atul S. ASLEKAR

Atul S. ASLEKAR has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Therapeutic agent for phosphodiesterase inhibition and its related disorders
    Patent number: 11786492
    Abstract: The pharmaceutical composition for treatment of phosphodiesterase related disorders comprises of administering to the subject a therapeutically effective amount of a compound of Formula-I, or compounds selected from the group consisting of Niclosamide, Oxyclozanide, Rafoxanide, Closantel, Dibromsalan, Metabromsalan, Tribromsalan and Nitazoxanide, and prodrugs, metabolites, or pharmaceutically acceptable salts, solvates and polymorphs thereof in a pharmaceutically acceptable carrier, vehicle, or diluents.
    Type: Grant
    Filed: September 15, 2021
    Date of Patent: October 17, 2023
    Assignees: Novalead Pharma Inc
    Inventors: Supreet K. Deshpande, Sudhir A. Kulkarni, Atul S. Aslekar
  • Therapeutic Agent For Phosphodiesterase Inhibition And Its Related Disorders
    Publication number: 20220000813
    Abstract: The pharmaceutical composition for treatment of phosphodiesterase related disorders comprises of administering to the subject a therapeutically effective amount of a compound of Formula-I, or compounds selected from the group consisting of Niclosamide, Oxyclozanide, Rafoxanide, Closantel, Dibromsalan, Metabromsalan, Tribromsalan and Nitazoxanide, and prodrugs, metabolites, or pharmaceutically acceptable salts, solvates and polymorphs thereof in a pharmaceutically acceptable carrier, vehicle, or diluents.
    Type: Application
    Filed: September 15, 2021
    Publication date: January 6, 2022
    Applicants: Novalead Pharma Inc
    Inventors: Supreet K. DESHPANDE, Sudhir A. KULKARNI, Atul S. ASLEKAR
  • Therapeutic agent for phosphodiesterase inhibition and its related disorders
    Patent number: 11147779
    Abstract: The pharmaceutical composition for treatment of phosphodiesterase related disorders comprises of administering to the subject a therapeutically effective amount of a compound of Formula-I, or compounds selected from the group consisting of Niclosamide, Oxyclozanide, Rafoxanide, Closantel, Dibromsalan, Metabromsalan. Tribromsalan and Nitazoxanide, and prodrugs, metabolites, or pharmaceutically acceptable salts, solvates and polymorphs thereof in a pharmaceutically acceptable carrier, vehicle, or diluents.
    Type: Grant
    Filed: March 14, 2018
    Date of Patent: October 19, 2021
    Assignees: Novalead Pharma Inc
    Inventors: Supreet K. Deshpande, Sudhir A. Kulkarni, Atul S. Aslekar
  • Therapeutic Agent For Phosphodiesterase Inhibition And Its Related Disorders
    Publication number: 20200022931
    Abstract: The pharmaceutical composition for treatment of phosphodiesterase related disorders comprises of administering to the subject a therapeutically effective amount of a compound of Formula-I, or compounds selected from the group consisting of Niclosamide, Oxyclozanide, Rafoxanide, Closantel, Dibromsalan, Metabromsalan. Tribromsalan and Nitazoxanide, and prodrugs, metabolites, or pharmaceutically acceptable salts, solvates and polymorphs thereof in a pharmaceutically acceptable carrier, vehicle, or diluents.
    Type: Application
    Filed: March 14, 2018
    Publication date: January 23, 2020
    Inventors: Supreet K. DESHPANDE, Sudhir A. KULKARNI, Atul S. ASLEKAR